Skip to main content

Eli Lilly and Company Value Stock - Dividend - Research Selection

Lilly

ISIN: US5324571083 , WKN: 858560

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer\'s disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Finally An Attractive Entry Point Into Novo Nordisk

2025-01-16
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.

Next Century Growth Investors Q4 2024 Commentary

2025-01-16
In the fourth quarter of 2024, equity markets were positive and large cap stocks generally outperformed small cap stocks. Read more here.

Tempering Positive Sentiment Of AI In Biotech

2025-01-16
AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.

Eli Lilly: FDA approves Omvoh for Crohn's disease

2025-01-16
Eli Lilly announces that the US Food and Drug Administration has approved Omvoh for the treatment of moderate to severe Crohn's disease in adults. Already approved in 2023 for ulcerative colitis,...

Correction to Eli Lilly Receives Approval for Crohn's Treatment Article

2025-01-15
Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. Eli Lilly Receives FDA Approval for Crohn's Disease Treatment, at 4:25 p.m. ET, and in a subsequent update, incorrectly...

Eli Lilly Receives FDA Approval for Crohn's Disease Treatment

2025-01-15
By Connor Hart Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes...

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

2025-01-15
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one yearAmong those who achieved clinical...

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

2025-01-15
Analysis of Eli Lilly and Company's stock performance and prospects in the dynamic weight-loss drug market, offering investment insights. Click for this LLY update.

Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

2025-01-14
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman and...

Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

2025-01-14
NEW YORK — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as...